Comparisons
9 min read
Tirzepatide vs Semaglutide
Side-by-side comparison of tirzepatide and semaglutide for weight loss in 2026. Mechanism, efficacy, cost, side effects, and which is right for you.
Read article →
Science & Mechanism
8 min read
How Tirzepatide Works
How tirzepatide produces weight loss through dual GLP-1 and GIP receptor activation. Mechanism, biology, and what makes it different from other GLP-1 medications.
Read article →
Outcomes & Expectations
7 min read
Expected Weight Loss on Tirzepatide
What weight loss to realistically expect on tirzepatide. SURMOUNT-1 trial results by dose, weekly weight loss patterns, and how to maximize results.
Read article →
Practical Guides
8 min read
How to Take Tirzepatide
Complete guide to taking tirzepatide injections in 2026. Dosing schedule, injection technique, missed-dose handling, and storage.
Read article →
Safety & Side Effects
9 min read
Tirzepatide Side Effects
Complete guide to tirzepatide side effects. Common GI effects, serious risks, FDA boxed warning, and how to manage adverse events through dose titration.
Read article →EvidenceScience-backed
SURMOUNT-5: Tirzepatide vs Semaglutide Head-to-Head (2025 Evidence)
What the 2025 SURMOUNT-5 head-to-head trial showed about tirzepatide versus semaglutide for weight loss, and what it means for telehealth patients.
Read article →EvidenceScience-backed
How Much Weight Loss on GLP-1s? The 2026 Trial Evidence
What clinical trials report for GLP-1 weight loss in 2026, from STEP and SURMOUNT to the latest head-to-head and oral-drug data.
Read article →EvidenceScience-backed
Oral GLP-1 Pills in 2025: Orforglipron and Oral Semaglutide Evidence
What 2025 trials showed about oral GLP-1 options — orforglipron (ATTAIN) and high-dose oral semaglutide (OASIS-4) — and what they mean for patients.
Read article →EvidenceScience-backed
Semaglutide Beyond Weight Loss: SELECT and FLOW Evidence
What the SELECT and FLOW trials showed about semaglutide's cardiovascular and kidney benefits, in plain language.
Read article →EvidenceScience-backed
GLP-1 Side Effects: What the Evidence Shows and How They're Managed
The most common GLP-1 side effects reported in trials, who should be cautious, and how titration and clinician oversight reduce them.
Read article →EvidenceScience-backed
Weight Regain After Stopping GLP-1s: What STEP-4 Found
What trials such as STEP 4 show about weight regain after stopping semaglutide, and what it means for long-term GLP-1 planning.
Read article →Frequently Asked Questions
How often are GLP1OneTelehealth articles updated?
Articles are reviewed on rolling cycles: practical guides and provider-related content every 60 days; clinical mechanism and trial content every 90 days; cost and regulatory content every 30-45 days. Last full editorial review: May 15, 2026.
Who writes these articles?
Articles are written by the GLP1OneTelehealth Editorial Team and reviewed for clinical accuracy against FDA prescribing information and peer-reviewed trial reports. Content is informational, not medical advice.
Can I cite these articles in academic or clinical work?
GLP1OneTelehealth articles are editorial in nature and not peer-reviewed clinical literature. For academic citations, please reference the primary sources we cite (FDA labels, published trials in NEJM, Lancet, JAMA, etc.) rather than this site directly.